Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21007247 | 0.92 | SETD7 (0.40) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL13567959 | 0.85 | NR1H2 (0.43) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL13568017 | 0.85 | NR1H2 (0.43) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL28950964 | 0.84 | NR1H2 (0.43) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL3967765 | 0.84 | SMARCA2 (0.41) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL3965455 | 0.84 | SMARCA2 (0.41) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL23867140 | 0.84 | NR1H2 (0.43) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL3965451 | 0.84 | SMARCA2 (0.41) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL1499106 | 0.84 | GPR119 (0.41) | SETD7GPR119NR1H2MEN1ALDH1A1 | |
| SCHEMBL28694792 | 0.83 | DRD3 (0.40) | SETD7GPR119NR1H2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697990-B | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12053469-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-115697990-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121422-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021194879-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | SETD7 2216/4885GPR119 2318/4885NR1H2 4052/4885 |
| US-20250114356-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | SETD7 2216/4885GPR119 2318/4885NR1H2 4052/4885 |
| US-12053469-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, MDM2 | SETD7 2216/4885GPR119 2318/4885NR1H2 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.